23andMe Eyes $1.7B Valuation With $200M Round

23andMe Eyes $1.7B Valuation With $200M Round
By 23andMe [Public domain], via Wikimedia Commons

Genetics company 23andMe is in the process of raising about $200 million, as first reported by TechCrunch. The funding will reportedly be led by Sequoia and come with a $1.7 billion valuation. 23andMe offers genetic services that provide users with information about their ancestry and personal health.

News of the round comes about five months after 23andMe scored a big win for one of its products, with the US Food and Drug Administration approving a saliva-based test that assesses a person’s genetic risk for Alzheimer’s, Parkinson’s and eight other diseases. Since it was founded in 2006, the Bay Area biotech has raised hundreds of millions—but co-founder and CEO Anne Wojcicki is said to be in no rush to IPO. Here’s a look at the company’s equity funding history:

May 2007: $9M funding | $45M valuation

This Clean Energy Hedge Fund Has Solid Returns In 2022 And Uses Amazon As A Precedent

global investment 1666792701Electron Capital returned 3.1% for October, bringing its year-to-date return to 8.3%. The MSCI ACWI gained 6% for October, raising its year-to-date return to -22.3%, while the S&P 500 returned 8% in October for a year-to-date loss of 18.8%. The MSCI World Utilities Index was up 2.7% for October but remains down 13.5% year to Read More

Dec. 2009: $27.8M | $138.9M

Jan. 2011: $31M | $179M

Dec. 2012: $58M | $288.7M

Oct. 2015: $115M | $1.1B

Want more info on 23andMe? Check out its free profile.

Article by PitchBook

No posts to display